FY2026 Earnings Estimate for AQST Issued By HC Wainwright

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities researchers at HC Wainwright issued their FY2026 earnings estimates for Aquestive Therapeutics in a research note issued to investors on Monday, March 10th. HC Wainwright analyst R. Selvaraju expects that the company will earn ($0.56) per share for the year. HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

Several other research analysts have also recently weighed in on AQST. Alliance Global Partners restated a “buy” rating on shares of Aquestive Therapeutics in a research report on Friday, March 7th. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 price objective on the stock. Raymond James set a $7.00 target price on Aquestive Therapeutics in a research note on Friday, March 7th. Finally, Lake Street Capital cut their target price on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 7th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Aquestive Therapeutics currently has a consensus rating of “Buy” and an average price target of $10.57.

Aquestive Therapeutics Trading Up 11.4 %

AQST stock opened at $2.94 on Tuesday. The company’s 50 day moving average is $3.04 and its 200 day moving average is $4.07. The stock has a market cap of $290.68 million, a price-to-earnings ratio of -6.53 and a beta of 2.76. Aquestive Therapeutics has a 1-year low of $2.24 and a 1-year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The company had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in shares of Aquestive Therapeutics by 905.2% in the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company’s stock worth $2,457,000 after purchasing an additional 621,614 shares during the last quarter. State Street Corp grew its holdings in shares of Aquestive Therapeutics by 52.1% in the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the last quarter. Stifel Financial Corp grew its holdings in shares of Aquestive Therapeutics by 315.4% in the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock worth $1,419,000 after purchasing an additional 302,617 shares during the last quarter. Harvey Capital Management Inc. grew its holdings in shares of Aquestive Therapeutics by 1,419.3% in the fourth quarter. Harvey Capital Management Inc. now owns 267,390 shares of the company’s stock worth $952,000 after purchasing an additional 249,790 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics in the third quarter worth approximately $995,000. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.